Mahaney Paige has filed 9 insider transactions across 1 company since October 2024.
Most recent transaction: a grant/award of 240000 shares of C4 Therapeutics, Inc. ($CCCC) on February 13, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | A | Common Stock | 240000 | $0.00 | 339,356.0000 | 96,914,418 | 241.56% | 0.25% |
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | F | Common Stock | 2446 | $1.89 | 336,910.0000 | 96,914,418 | 0.72% | 0.00% |
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | M | Common Stock | 7050 | $0.00 | 339,356.0000 | 96,914,418 | 2.12% | 0.01% |
| Oct. 28, 2025 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | M | Common Stock | 19200 | $0.00 | 105,000.0000 | 70,989,661 | 22.38% | 0.03% |
| Oct. 28, 2025 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | F | Common Stock | 5644 | $2.58 | 99,356.0000 | 70,989,661 | 5.38% | 0.01% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | A | Stock Option (Right to Buy) | 42400 | $0.00 | 42,400.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | A | Common Stock | 28200 | $0.00 | 105,000.0000 | 0 | 36.72% | 0.00% |
| Oct. 28, 2024 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | A | Stock Option (Right to Buy) | 345600 | $0.00 | 345,600.0000 | 0 | 9999.99% | 0.00% |
| Oct. 28, 2024 | C4 Therapeutics, Inc. | $CCCC | Mahaney Paige | Chief Scientific Officer | A | Common Stock | 76800 | $0.00 | 76,800.0000 | 0 | 9999.99% | 0.00% |